Literature DB >> 3767344

Activity of roxithromycin (RU 28965), a macrolide, against Toxoplasma gondii infection in mice.

J Chan, B J Luft.   

Abstract

Roxithromycin (RU 28965), an ether oxime derivative of erythromycin, protected mice against a lethal infection with the virulent RH strain of Toxoplasma gondii. Therapy begun 24 h before, 2 h after, and 24 h after infection with 2 X 10(3) tachyzoites protected 90, 80, and 50% of the mice, compared with 0% of untreated controls (P less than 0.05 to 0.001). Toxoplasma was isolated in less than 20% of surviving roxithromycin-treated mice.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3767344      PMCID: PMC180543          DOI: 10.1128/AAC.30.2.323

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  The clinical toxicity of antibiotics and sulfonamides; a comparative review of the literature based on 104, 672 cases treated systemically.

Authors:  A H KUTSCHER; S L LANE; R SEGALL
Journal:  J Allergy       Date:  1954-03

2.  Effect of pregnancy on augmentation of natural killer cell activity by Corynebacterium parvum and Toxoplasma gondii.

Authors:  B J Luft; J S Remington
Journal:  J Immunol       Date:  1984-05       Impact factor: 5.422

3.  In vitro comparison of the activity of RU 28965, a new macrolide, with that of erythromycin against aerobic and anaerobic bacteria.

Authors:  T Barlam; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

4.  Trimethoprim-sulfamethoxazole in murine toxoplasmosis.

Authors:  J S Remington
Journal:  Antimicrob Agents Chemother       Date:  1976-02       Impact factor: 5.191

5.  In vitro evaluation of three new macrolide antimicrobial agents, RU28965, RU29065, and RU29702, and comparisons with other orally administered drugs.

Authors:  R N Jones; A L Barry; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

6.  The hematologic toxicity of pyrimethamine (daraprim) in man.

Authors:  H E KAUFMAN; P H GEISLER
Journal:  Arch Ophthalmol       Date:  1960-07

7.  Pharmacological studies of pyrimethamine (daraprim) in man.

Authors:  H E KAUFMAN; L A CALDWELL
Journal:  AMA Arch Ophthalmol       Date:  1959-06
  7 in total
  18 in total

Review 1.  New directions for macrolide antibiotics: structural modifications and in vitro activity.

Authors:  H A Kirst; G D Sides
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

2.  Unpredictable influence of human serum on antimicrobial activity of erythromycin and three oxime ether macrolides.

Authors:  R N Jones; A L Barry
Journal:  Eur J Clin Microbiol       Date:  1987-02       Impact factor: 3.267

Review 3.  Current problems in the management of AIDS patients.

Authors:  N Clumeck; P Hermans; S De Wit
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-02       Impact factor: 3.267

Review 4.  Clinically Available Medicines Demonstrating Anti-Toxoplasma Activity.

Authors:  Andrew J Neville; Sydney J Zach; Xiaofang Wang; Joshua J Larson; Abigail K Judge; Lisa A Davis; Jonathan L Vennerstrom; Paul H Davis
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

5.  Assessment of spiramycin-loaded chitosan nanoparticles treatment on acute and chronic toxoplasmosis in mice.

Authors:  Samia E Etewa; Dalia A Abo El-Maaty; Rania S Hamza; Ashraf S Metwaly; Mohamed H Sarhan; Sara A Abdel-Rahman; Ghada M Fathy; Mahmoud A El-Shafey
Journal:  J Parasit Dis       Date:  2017-12-15

6.  In vitro and in vivo effects of doxycycline on Toxoplasma gondii.

Authors:  H R Chang; R Comte; J C Pechère
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

7.  In vivo activity of the macrolide antibiotics azithromycin, roxithromycin and spiramycin against Toxoplasma gondii.

Authors:  F G Araujo; R M Shepard; J S Remington
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-06       Impact factor: 3.267

8.  Localization of azithromycin in Toxoplasma gondii-infected cells.

Authors:  J C Schwab; Y Cao; M R Slowik; K A Joiner
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

9.  Comparative activity of macrolides against Toxoplasma gondii demonstrating utility of an in vitro microassay.

Authors:  S Chamberland; H A Kirst; W L Current
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

10.  Effect of roxithromycin on acute toxoplasmosis in mice.

Authors:  H R Chang; J C Pechere
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.